15 Nov 2022

Newly debuted on HKEX in July this year, MicroPort NeuroTech (MNT) is a medical device company for treating neurovascular disease. Since its first product approval in 2004, the company has built up a diversified products portfolio for neuro-interventional diseases with a total 30 products, including 10 therapeutic products and 3 access products approved and commercialized in China and 17 pipeline products under different development stages. MNT expects 17 products shall obtain NMPA approval in the next five years, out of which, 5 to receive approval next year. The company boasts a comprehensive portfolio covering three major areas of neurovascular disease, namely hemorrhagic stroke (HS), cerebral atherosclerotic stenosis (CAS) and acute ischemic stroke (AIS). Currently, MNT owns about 8% of market share in China, securing the largest domestic medical device developer spot in an industry that is largely dominated by the foreign developers.

CROSBY Research – Microport NeuroTech (2172 HK): A premium Chinese neuro-interventional medical device play